English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, April 3, 2023
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
エーザイ、抗がん剤タゼメトスタットについて、「患者申出療養」制度に基づく医師主導臨床研究への協力に関する契約を国立がん研究センターと締結
Friday, March 31, 2023
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
Friday, March 24, 2023
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
エーザイ、米国婦人科腫瘍学会(SGO)2023 Annual Meeting on Women's Cancerにおいてオンコロジー領域の臨床研究の演題を発表
Thursday, March 23, 2023
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
Tuesday, July 26, 2022
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
Wednesday, July 6, 2022
エーザイ、抗アミロイドβ(Aβ)プロトフィブリル抗体「レカネマブ」について、迅速承認制度に基づく、早期アルツハイマー病に対する生物製剤ライセンス申請が米国FDAに受理され、優先審査に指定
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575